Therefore, we propose that PD-L2 represents an additional component of a multifaceted immune evasion program regulated by FAK in pancreatic cancer and that high expression of PD-L2 may also represent a potential biomarker for the identification of patients more likely to benefit from treatment with a FAK inhibitor. The gene discussed is PTK2; the disease is pancreatic neoplasm.